

REINS - Enhancing Patient Engagement in Neurofibromatosis Clinical Trials



Washington December 5, 2016

Increasing patient engagement in arthritis studies: the OMERACT experience

Disclosures



REiNS objectives

- To educate neurofibromatosis researchers and clinicians about the utility of increased patient engagement in developing endpoints for clinical trials
- 2. To engage patients, family members, and other stakeholders in the NF community in the REiNS collaboration
- To generate a roadmap for developing patient engagement guidelines in REiNS subgroups





Part 1

Part 2

 \mathbf{M}

Overview

To educate neurofibromatosis
researchers and clinicians about the
utility of increased patient
engagement in developing
endpoints for clinical trials

How to engage patients, family members, and other stakeholders in the NF community in the REiNS collaboration

To generate a roadmap for developing patient engagement

developing patient engagemer guidelines in REiNS subgroups



Part I

"Researchers can easily overlook the complexity and capriciousness of living with a chronic disease, reducing the meaning of life experiences to abstract themes and models". *

* Schipper, K. (2011). *Patient participation & knowledge [thesis]*. VU University, Amsterdam (p.232)



"Where do we come from?"

"Where are we going?"



- The patient as passive recipient, following doctor's prescription
- One way communication
- Patient is study participant



- The patient as an equal partner in the decision making process
- Two way communication
- Patient as collaborative partner

Why actively involving patients in health research?

Ethical argument

In a democracy patients have the right to speak for them selves

Content argument

Experience based knowledge makes research outcomes more relevant and fitting better with the context of daily life

Political argument Legitimacy and chances for implementation increase

Empowerment of patients and researchers



Have a say in science

Patient participation in theory and practice

Abma & Broerse 2007 Biannual worlwide conference on: Outcome Measurement in Rheumatology Clinical Trials



- First conference in 1992 in Maastricht
- Aim: To achieve consensus about endpoints for clinical trials in rheumatology
- Characteristics:
 - Data-driven, iterative consensus process
 - Inclusive, interactive, non-commercial
 - A broad stakeholders approach

Tugwell P, Boers M, OMERACT Conference on outcome measures in Rheumatoid Arthritis clinical trials: Introduction, Jrn of Rheum 1993;**20**:3 528-530.

OMERACT agrees 'core sets' for measuring outcome in rheumatic diseases

At OMERACT 1 (1992) the core set for rheumatoid arthritis (RA) was agreed

- Pain
- Swollen joints
- Tender joints
- Physician global assessment
- Patient global assessment
- Physical function
- Acute phase response



M. Boers, P. Tugwell, D.T. Felson, et al , World Health Organization and International League of Associations for Rheumatology Core Endpoints for Symptom Modifying Antirheumatic Drugs in RA Clinical Trials , Jrn Rheum 1994, **21**, WHO/ILAR suppl.

Why involving patients in OMERACT 5 outcome research?

- In 2000 OMERACT participants discussed the definition of a 'clinically important change' in response to treatment.
- In the final voting session participants agreed that this questions could only be answered by patients.

For OMERACT 6 (2002) 11 patients were invited to review the OMERACT core set.







Involving patient research partners has a significant impact on outcomes res<u>earch: a responsive evaluation of the</u>

int Maart

John

To cite: de Wit M, Abma T, Koelewijn-van Loon M, et al. Involving patient research partners has a significant impact on outcomes research: a responsive evaluation of the international OMERACT conferences. BMJ Open 2013;3:e002241. doi:10.1136/bmjopen-2012-002241

Prepublication history for this paper are available online. To view these files please visit the journal online (http://dx.doi.org/10.1136/ bmjopen-2012-002241).

ABSTR Objecti internati Rheuma has influ research Design internal proceed

includin

Settina



RHEUMATOLOGY RESEARCH A four level responsive evaluation

Maarten de Wit

conference ownerAct to (malaysia, 2010). **Participants:** Senior researchers (n=10), junior researchers (n=2), representatives of the pharmaceutical industry and regulators (n=2), conference staff (n=2), new patient delegates (n=8) and experienced patient delegates (n=2)

ACT conferences

elewijn-van Loon,² Sarah Collins,³

ARTICLE SUMMARY

Article focus

- Since 2002, patients have participated as collaborative partners in the biannual conference on Outcome Measures in Rheumatology (OMERACT).
- Although the contribution of patients has been praised and there is a widespread call for scientific publications on the impact of engaging with patients, no systematically obtained evidence has been published to support the idea that the structural involvement of patients in research conferences is beneficial.
- Our qualitative study reports the combined results of a thematic document analysis and 32 semistructured interviews with all stakeholders including researchers, patient participants, and



The example of fatigue in RA



Early descriptions at OMERACT 6 & 7 led to substantial qualitative research establishing the importance of RA fatigue


"Fatigue is overwhelming and different from normal tiredness; it permeates every sphere of life; and self-management is variable, but professional support is rare"

Hewlett S, et al. Patients' perceptions of fatigue in rheumatoid arthritis: overwhelming, uncontrollable, ignored. *Arthritis Rheum* 2005

Nicklin, J., et al., Collaboration with patients in the design of patient-reported outcome measures: Capturing the experience of fatigue in rheumatoid arthritis. *Arthritis Care Res* 2010.

Qualitative work showed that measuring fatigue adds new information to the existing core set for RA


May 10th - 14th 2006



Contribution of different variables to measuring rheumatoid arthritis

Pain Fatigue Clinician Global Patient Global Rheumatoid Red: Variance in measure Arthritis that can be accounted for (explained) by variation in the other measures Swollen Joints Tender Joints Disability John Kirwan, 2006 10th - 14th 2006

Contribution of different variables to measuring rheumatoid arthritis



Result

- Fatigue was added to the core-set, to be included as outcome in every new clinical trial in RA.
- More powerful instruments for measuring fatigue in RA have now been devised, and are increasingly used in clinical trials.

This would never have happened without the direct involvement of patient delegates in the OMERACT process



"We were first discussing on fatigue and to be honest I never ever had before heard of fatigue being a problem in rheumatology. So it got into my mind and then I got thinking about it and then, when I was back, I asked patients if they felt fatigue and I got nearly a 100% positive response. So it was like a coming out, you know. I listened to the patients before but bringing it to a specific topic, that was really what I learned at OMERACT." [RC]

"We were first discussing on fatigue and to be honest I never ever had before heard of fatigue being a problem in rheumatology. So it got into my mind and then I got thinking about it and then, when I was back, I asked patients if they felt fatigue and I got nearly a 100% positive response. So it was like a coming out, you know. I listened to the patients before but bringing it to a specific topic, that was really what I learned at OMERACT." [RC]

"We were first discussing on fatigue and to be honest I never ever had before heard of fatigue being a problem in rheumatology. So it got into my mind and then I got thinking about it and then, when I was back, I asked patients if they felt fatigue and I got nearly a 100% positive response. So it was like a coming out, you know. I listened to the patients before but bringing it to a specific topic, that was really what I learned at OMERACT." [RC]

Conclusion

"Clinical trials are only as credible as their endpoints" *


* Peter Tugwell & Maarten Boers, The Journal of Rheumatology 1993; 20:3

Part II


Core domain set development according to the OMERACT filter 2.0

Boers M, Kirwan J, Tugwell P, et al. The OMERACT Handbook. In: OMERACT; 2014. Boers M, Kirwan JR, Wells G, et al. Developing core outcome measurement sets for clinical trials: OMERACT filter 2.0. J Clin Epidemiol 2014;67(7):745-53.


OMERACT disease specific core domain sets



OMERACT Filter 2.0: Developing a Core Domain Set



Template of an OMERACT core domain set





COMET- Core Outcome Measures in Effectiveness Trials

- Core outcome set (COS) is an agreed standardized set of outcomes to be measured an reported as a minimum in all trials in a specific health related area.*
 - COMET database is an international repository of studies relevant to the development of COS, planned, ongoing and completed.**

* Gargon E, et al. Choosing important health outcomes for comparative effectiveness research: a systematic review. PLoS One [internet], 2014; 9(6):[e99111 p.]. Available from: 10.1371/journal.pone.0099111. ** www.comet-initiative.org





PLOS ONE

Choosing Important Health Outcomes: Updated Review and User Survey








Fig 3. Number of COS developed in each disease category (n = 227).

doi:10.1371/journal.pone.0146444.g003









Need to update the PsA core set with active patient

involvement

Tillett W, Eder L. Enhanced patient involvement and the need to revise the core set- report from the PsA workshop at OMERACT 2014. Jrn of Rheum, 2015

A best practice of patient participation in COS development

Updating the core domain set for Psoriatic Arthritis

Orbai, A. et al. Annals of Rheum Diseases 2016



Methods of involvement


Patient participation – following OMERACT recommendations*

The patient voice was sought through

- 1. Active partnership of five patient research partners (PRPs) in the working group and one PRP in the Steering Group
- 2. International focus group study representing five continents and including seven countries
- 3. Delphi study
- 4. Consensus meeting

- Cheung PP ea Recommendations for the Involvement of Patient Research Partners (PRP) in OMERACT Working Groups. *The Journal of rheumatology* 2016;43(1):187-93)
- De Wit M ea, Successful Stepwise Development of Patient Research Partnership: 14 Years' Experience of Actions and Consequences in OMERACT, *The Patient* 2016,

Trying to ensure representativeness



Work streams Update core outcome set for Psoriatic Arthritis



Following OMERACT recommendations

The Journal of Rheumatology

Recommendations for the Involvement of Patient Research Partners (PRP) in OMERACT Working Groups. A Report from the OMERACT 2014 Working Group on PRP

Peter P. Cheung, Maarten de Wit, Clifton O. Bingham 3rd, John R. Kirwan, Amye Leong, Lyn M. March, Pam Montie, Marieke Scholte-Voshaar, and Laure Gossec

ABSTRACT. Objective. Patient participation in research is increasing; however, practical guidelines to enhance this participation are lacking. Specifically within the Outcome Measures in Rheumatology (OMERACT) organization, although patients have participated in OMERACT meetings since 2002, consensus about the procedures for involving patients in working groups has not been formalized. The objective is to develop a set of recommendations regarding patient research partner (PRP) involvement in research working groups.

What about PRPs Tasks?

	Steering group	Working group	Study design	SLR	FG protocol	FG moderation analysis	Delphi Design	NGT meeting
PRP 1		Х	Х	Х	X	Х	Х	X
PRP 2		Х	Х		X		X	Х
PRP 3		Х	Х	Х	Х		Х	Х
PRP 4	Х	Х	Х	Х	X	Х	Х	Х
PRP 5					X			
PRP 6					Х			
PRP 7					Х	Х	Х	Х
PRP 8								
PRP 9								
PRP 10								
PRP 11		Х	Х	Х	Х			
PRP 12								
PRP 13						Х		
PRP 14					Х			
TOTAL	1	5	5	4	9	4	5	5

What about PRPs' recognition? Co-authorship

	Steering group	Working group	Study design	SLR 1	FG protocol	FG moderation	Delphi Design	NGT meeting
						analysis		
PRP 1		Х	Х	Х	Х	Х	Х	Х
PRP 2		Х	Х		X		Х	Х
PRP 3		Х	Х	Х	Х		Х	Х
PRP 4	Х	Х	Х	Х	Х	Х	Х	Х
PRP 5					Х			
PRP 6					Х			
PRP 7					Х	Х	Х	Х
PRP 8								
PRP 9								
PRP 10								
PRP 11		X	Х	X	X			
PRP 12								
PRP 13						X		
PRP 14					Х			
TOTAL	1	5	5	4	9	4	5	5

Extended PRP involvement

	Steering group	Working group	Study design	SLR 1	FG protocol	FG moderation analysis	Delphi	NGT meeting
PRP 1		Х	Х	Х	X	X	Х	Х
PRP 2		Х	Х		X		X	Х
PRP 3		Х	Х	Х	Х		Х	Х
PRP 4	Х	Х	Х	Х	X	Х	Х	Х
PRP 5					X		X	X
PRP 6					Х		X	X
PRP 7					Х	Х	X	X
PRP 8							X	Х
PRP 9							X	X
PRP 10							X	X
PRP 11		Х	Х	Х	Х		X	X
PRP 12							X	X
PRP 13						Х		
PRP 14					Х		X	
TOTAL	1	5	5	4	4	4	13	12

PRP participation as integral part of research Evolving Patient Roles


Control Collaboration **Advice** consultation

Steering group member

Patient research partners


Delphi participants

Focus group participants



Diseases 2016

Economic costs



What were challenges of involving patients in the COS update process?

- 1. Unanticipated Work Load for PRPs and researchers
- 2. Communication and equal collaboration

How to enhance new approaches and attitudes

3. Ensuring broad representativeness of patients' perspectives

In demography, geography, disease severity and in numbers

- 4. Keeping PRPs and researchers motivated to collaborate
- 5. Preserving the patient perspective throughout the research process

What were challenges of involving patients in the COS update process?

- 1. Unanticipated Work Load for PRPs and researchers
- 2. Communication and equal collaboration

How to enhance new approaches and attitudes

3. Ensuring broad representativeness of patients' perspectives,


In demography, geography, disease severity and in numbers


- 4. Keeping PRPs and researchers motivated to collaborate
- 5. Preserving the patient perspective throughout the research process


Preserving the patients' perspectives


- Core domain sets should be short and feasible to measure, and based on stakeholder input and consensus.
- But how can we guarantee that consensus is obtained without losing important domains for patients and hence content validity of the core set?

PRP participation as integral part of the consensus building












Orbai AM ea, International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. *Annals of the rheumatic diseases* 2016.





- Full day consensus meeting
- Equal representation
- Independent facilitator
- Open dialogue


Preliminary consensus on the updated PsA core domain set











What has been the impact of patient and PRP involvement?

- PRP involvement in coding focus group transcripts ensured domains important to patients were captured.
- PRP involvement in developing the domain Delphi list ensured that domain descriptions were phrased in a manner understandable to patients.
- Integration of the patient perspective in a meaningful and representative manner provided face validity to the COS
- PRP involvement in the consensus process resulted in new domains on the research agenda and in the middle core. No patient relevant domains were added to the inner core.

How can this be explained?

Potential factors to look at....

- Risk of patient representatives aligning with physicians views and priorities?
- Influence of existing power imbalances?
- Influence of clinical relationships?
- Lack of proportional representation in numbers?



Domecq JP et al. Patient engagement in research: a systematic review. *BMC Health Serv Res* 2014;14(1):89.

Boote J et al. Involving the public in systematic reviews: a narrative review of organizational approaches and eight case examples. *J Comp Eff Res* 2012;1(5):409-20.

Oliver SR, Rees RW, Clarke-Jones L, Milne R, Oakley AR, Gabbay J, et al. A multidimensional conceptual framework for analysing public involvement in health services research. *HEX* 2008;11(1):72-84.

Staniszewska S et al. Patient and public involvement in patient-reported outcome measures: evolution not revolution. *Patient* 2012;5(2):79-87.

Legare F et al. Patient and public involvement in clinical practice guidelines: a knowledge synthesis of existing programs. *Med Decis Making* 2011;31(6):E45-74.

Serrano-Aguilar P et al. Patient involvement in health research: a contribution to a systematic review on the effectiveness of treatments for degenerative ataxias. *Social science & medicine* 2009;69(6):920-5.

Staley K. Exploring Impact: Public involvement in NHS, public health and social care research. Eastleigh: INVOLVE, 2009:116.

Brett J et al. The PIRICOM Study: A systematic review of the conceptualisation, measurement, impact and outcomes of patients and public involvement in health and social care research. The University of Warwick, 2009.

Mockford et al. The impact of patient and public involvement on UK NHS health care: a systematic review. *Int J Qual Health Care* 2012;24(1):28-38.

Barber R et al. Evaluating the impact of public involvement on research. In: *Critical Perspectives on User Involvement*. Bristol, 2012:217-23.

Crawford MJ et al. Systematic review of involving patients in the planning and development of health care. *BMJ* 2002;325(7375):1263.

Brett J et al. Mapping the impact of patient and public involvement on health and social care research: a systematic review. *Health expectations*, 2012.

Publications

- **De Wit M**, Abma T, Koelewijn-van Loon M, Collins S, Kirwan J. Involving patient research partners has a significant impact on outcomes research: a responsive evaluation of the international OMERACT conferences. *BMJ Open* 2013;3:e002241 Doi:10.1136/bmjopen-2012-002241
- **De Wit M**, Koelewijn-van Loon MS, Collins S, Abma TA, Kirwan JR. "If I wasn't this robust": Patients' expectations and experiences at the Outcome Measures in Rheumatology Conference 2010. *The Patient* 2013;2013/06/06. Doi: 10.1007/s40271-013-0017-0.
- De Wit M, Abma TA, Koelewijn-van Loon M, Collins S, Kirwan J. Facilitating and inhibiting factors for long term involvement of patients in outcome research - Lessons learned from a decade of collaboration at OMERACT conferences. *BMJopen* 2013;3:e003311 Doi:10.1136/bmjopen-2013-003311
- De Wit M, Abma TA, Koelewijn-van Loon M, Collins S, Kirwan J. What have we learned from a decade of patient participation in OMERACT and its effect on trial outcome assessments? *The Journal of rheumatology* 2014;41(1):177-84.
- de Wit M, Kirwan JR, Tugwell P, et al. Successful Stepwise Development of Patient Research Partnership: 14 Years' Experience of Actions and Consequences in Outcome Measures in Rheumatology (OMERACT). Patient 2016.
- de Wit M, Elberse JE, Broerse JE, Abma TA. Do not forget the professional the value of the FIRST model for guiding the structural involvement of patients in rheumatology research. *Health expectations*. 2015; 18: 489-503
- De Wit M, Kvien T, Gossec L. Patient participation as an integral part of patient reported outcomes development guarantees the representativeness of the patient voice – A case-study from the field of rheumatology. RMD-open 2015;1.
 - **de Wit M**, Berlo SE, Aanerud GJ, Aletaha D, Bijlsma JW, Croucher L, et al. European League Against Rheumatism recommendations for the inclusion of patient representatives in scientific projects. Annals of the rheumatic diseases 2011;70:722-6.

Conditions for participation


- Participation is a process
- The role of the principal investigator is key in providing adequate support to patients
- Participation should always be tailor made, there is no concept that fits all
- It requires multiple forms of participation
- It requires always an extra effort: in time, money and energy
- A structural approach guarantees sustainability
- Willingness for mutual learning

Conclusion

- PRP involvement is needed to ensure face validity of a core domain set.
- Attributes for an effective consensus meeting are:
 - Equal numbers of patients and other stakeholders
 - An independent facilitator
 - Open dialogue
 - Inclusion of opinions of all participants via consensus techniques (Nominal Group Technique).
- More research is needed to explore strategies to preserve the patients' perspectives in the consensus building process and final core domain set.

Thanks for your attention





martinusdewit@hotmail.com